Evidence map›Paper›PMID 40088185›Full record

Trial reportThe oncologist2025

Aumolertinib plus chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R: a phase II trial.

Yanwei Li, Chenguang Li, Xiaoliang Zhao, Yong Li, Feng He, Zhanyu Pan

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04646824 (A Study of Almonertinib With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04646824 phase2unknown statusnot on this map

A Study of Almonertinib With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer

TypeinterventionalSponsorTianjin Medical University Cancer Institute and HospitalRan2020 to 2022Enrolled10ConditionsNon-Small Cell Lung Cancer MetastaticArmsAlmonertinib Pemetrexed/Cisplatin
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Observational
  2. Observational
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yanwei LiDepartment of Integrated Traditional and Western Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, People'sRepublic of China.ORCID 0000-0003-3828-9754
Chenguang LiAcademy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin 300192, People's Republic of China.
Xiaoliang ZhaoAcademy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin 300192, People's Republic of China.
Yong LiAcademy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin 300192, People's Republic of China.
Feng HeDepartment of Integrated Traditional and Western Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, People'sRepublic of China.
Zhanyu PanAcademy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin 300192, People's Republic of China.

Funding

Science and Technology Project of Tianjin Municipal Health Commission no. ZC20169Tianjin Key Medical Discipline (Specialty) Construction Project no. TJYXZDXK-010A
6 · The paper itself

Abstract

backgroundTo evaluate the efficacy and safety of aumolertinib combined with pemetrexed and carboplatin as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation (exon 19 deletion or exon 21 L858R).

methodsIn phase II trial (NCT04646824), patients received aumolertinib 110 mg once daily plus pemetrexed (500 mg/m2) and carboplatin (area under curve = 5) once every 3 weeks for 4 cycles, followed by maintenance aumolertinib (110 mg once daily) and pemetrexed (500 mg/m2 once every 4 weeks). The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety.

resultsFrom November 2020 to October 2021, 34 patients were included for analysis. The median PFS was 28.0 months (95% CI, 18.7-36.9). The ORR was 91.2% (31/34), and the DCR was 100%. The median OS was not reached. Of 28 patients with circulating tumor DNA (ctDNA) testing, 22 (78.6%) showed clearance of EGFR mutation after 2 or 4 cycles. The median PFS was 31 months in patients with EGFR mutation clearance in ctDNA, and the ORR of them was higher than those without EGFR mutation clearance in ctDNA (90.9% vs 33.3%). The most common grade ≥ 3 treatment-related adverse event was decreased neutrophil count (22 [64.7%]).

conclusionAumolertinib plus chemotherapy shows potential as first-line treatment for patients with EGFR-mutant advanced NSCLC, which deserves to be investigated in randomized controlled trials. CtDNA clearance may be a prognostic marker.

Indexed as

AcrylamidesAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungLung NeoplasmsAdultAgedCarboplatinErbB ReceptorsExonsFemaleHumansMaleMiddle AgedPemetrexedAcrylamidesCarboplatinEGFR protein, humanErbB ReceptorsPemetrexedaumolertinibEGFR mutationnon-small cell lung cancerplatinum-based chemotherapy

Identifiers

PMID40088185
PMCPMC11909725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.